LSD1 is a targetable vulnerability in gastric cancer harboring TP53 frameshift mutations
In summary, our results indicate that the nuclear localization deficiency of p53 accounts for increased expression of LSD1 in TP53 Frameshift <sup>NLS</sup> GCs. GSK690 inhibits cell cycle progression and tumor growth by suppressing aberrantly activated LSD1-CCNA2 signaling in this GC subtype, counteracting malignant proliferation and thereby providing a precise therapeutic strategy for GC patients with TP53 Frameshift <sup>NLS</sup>.
Authors
- Junhui Tang
- Surui Yao (ORCID: https://orcid.org/0000-0002-1585-8101)
- Chunyu Yang (ORCID: https://orcid.org/0000-0002-1590-1712)
- Kaiqing Wang
- Bojian Fei (ORCID: https://orcid.org/0000-0002-3672-0216)
- Zhaohui Huang (ORCID: https://orcid.org/0000-0002-0117-9976)
- Hao Cheng (ORCID: https://orcid.org/0000-0001-5075-1329)
- Suzeng Wang
Institutions
- Jiangnan University (CN)
- Wuxi Fourth People's Hospital (CN)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1186/s13148-025-01829-9
- Citations
- 5
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 4.03